1 / 16

A Metabolomic Approach to the Identification of Cancer Biomarkers

A Metabolomic Approach to the Identification of Cancer Biomarkers. Clive Baveghems Bioanalytical Chemistry Spring 2011. Outline. What is Metabolomics? Metabolomic screening for the identification of cancer biomarkers Metabolomic screening for the identification of prostate cancer biomarkers.

flynn
Download Presentation

A Metabolomic Approach to the Identification of Cancer Biomarkers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Metabolomic Approach to the Identification of Cancer Biomarkers Clive Baveghems Bioanalytical Chemistry Spring 2011

  2. Outline • What is Metabolomics? • Metabolomic screening for the identification of cancer biomarkers • Metabolomic screening for the identification of prostate cancer biomarkers

  3. Introduction to Metabolomics Sawyer, J. Surg. Oncol. 2010; 21831: 2

  4. Yearly increase in Metabolomics publications Note: 2010 total ~ 750 Ong, Trends in Analytical Chemistry 2010; 29(3):270

  5. Factors influencing the Metabolome Sawyer, J. Surg. Oncol. 2010; 21831: 2

  6. Outline • What is Metabolomics?√ • Metabolomic screening for the identification of cancer biomarkers • Metabolomic screening for the identification of prostate cancer biomarkers

  7. Biomarker Identification Sawyer, J. Surg. Oncol. 2010; 21831: 4

  8. Cancer biomarkers identified so far Sawyer, J. Surg. Oncol. 2010; 21831: 5

  9. Key Metabolites implicated so far Sawyer, J. Surg. Oncol. 2010; 21831: 6

  10. Outline • What is Metabolomics?√ • Metabolomic screening for the identification of cancer biomarkers√ • Metabolomic screening for the identification of prostate cancer biomarkers

  11. Prostate Cancer • From 2003-2007 median age for diagnosis was 67 • The age-adjusted incidence rate was 156.9/100, 000 men per year • The median age at death was 80 • The age-adjusted death rate was 24.7/100, 000 men per year http://seer.cancer.gov/statfacts/html/prost.html

  12. Results from LC and GC-MS Chinnaiyan, Nature 2009; 457(12): 911

  13. Sarcosine identified as a biomarker for prostate cancer Chinnaiyan, Nature 2009; 457(12): 913

  14. Is sarcosine a biomarker for prostate cancer? GC-MS data Jung, Journal of Urology 2011; 185: 708

  15. Summary • Metabolomics has emerged as a fast and efficient method for the identification of a small set of candidate biomarkers from a large eclectic data set • LC/MS, GC/MS, and NMR are important metabolomic technologies • Future studies will further explain sarcosine’s role in Prostate Cancer

  16. References • Metabolomics and Surgical Oncology: Potential Role for Small Molecule BiomarkersSawyer, J. Surg. Oncol. 2010; 21831: 1-9 • Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionChinnaiyan, Nature 2009; 457(12): 910-915 • Sarcosine in Prostate Cancer Tissue is Not a Differential Metabolite for Prostate Cancer Progressiveness and Biochemical ProgressionJung, Journal of Urology 2011; 185: 706-711 • Experiment-originated variations, and multi-peak and muti-origination phenomena in derivatization-based GC-MS metabolomicsOng,Trends in Analytical Chemistry 2010; 29(3):269-280

More Related